T1	Participants 52 100	cytomegalovirus retinitis in patients with AIDS.
T2	Participants 226 282	patients with acquired immunodeficiency syndrome (AIDS).
T3	Participants 575 680	two doses (165-microg/injection [35 eyes, 30 patients] and 330-microg/injection [153 eyes, 120 patients])
